WuXi AppTec Inc.
Division of WuXi PharmaTech Inc.
Latest From WuXi AppTec Inc.
A new rule regulating the collecting, storing and transporting of genetic samples and materials in China sets new limits on international companies looking to conduct work with biologic and gene therapies in potentially the most promising market for these emerging technologies.
An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.
The coming of spring has seen the announcement of multiple executive moves in the Asia Pacific region, including a new CEO at Japan's Daiichi Sankyo, while WuXi Apptec and llumina have also made new appointments. Other personnel changes also take place at Shionogi Healthcare and the top of Japan's main regulatory agency.
South Korea’s first approved gene therapy has been suspended from sale in the country, while recruitment in an ongoing US Phase III program has been temporarily halted, after findings that an active cell component may differ from the data submitted at the time of approval. While both manufacturer and regulator see no safety risk, results from an official Korean probe are due in mid-April.
- Contract Research, Toxicology Testing-CRO
- Medical Devices
- Therapeutic Areas
- AppTec Laboratory Services Inc.
- Parent & Subsidiaries
- WuXi PharmaTech Inc.
- Senior Management
Edward Hu, Co-CEO
Ellis Chu, SVP, CFO
Shuhui Chen, PhD, CSO
Steve Yang, PhD, EVP, CBO
Frederick H Hausheer, MD, CMO
- Contact Info
WuXi AppTec Inc.
Phone: 21 5046 1111
Waigaoqiao Free Trade Zone
288 Fute Zhong
Shanghai, MN 200131
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.